Young people who have been living with HIV since birth have a significant unmet need for innovative long-acting treatments that can overcome drug resistance and adherence challenges, a London study has concluded. These individuals should be a priority group for inclusion in clinical trials and implementation studies of long-acting treatments, the researchers say.
The study found that over one in three young people with HIV had drug resistance patterns that could make them ineligible for injectable long-acting treatment with cabotegravir and rilpivirine.
Read the full news story at aidsmap.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.